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FlexibilityAmyloid ﬁbrillar aggregates of proteins or peptides are involved in the etiology of several neurodegener-
ative diseases and represent a major problem in healthcare. Short regions in the protein trigger this
aggregation. It is important to understand the basis of such short regions aggregation and amyloidosis
for therapeutic intervention. In this study, we describe speciﬁc physico-chemical properties of amyloido-
genic segments and compare them with non-amyloidogenic segments. First, amyloidogenic segments are
characterized by lower values for average net charge, electrostatic potential, solvent accessible surface
area and B-factor when compared to the non-amyloidogenic segments of the same proteins. Second, they
are enriched in hydrophobic residues and have a tendency to form hydrogen bonds. Thus, amyloidogenic
segments have distinct physico-chemical properties that are different from those of non-amyloidogenic
segments. Third, and quite unexpectedly, our dynamic simulation studies support the hypothesis that
amyloidogenic segments have lower average ﬂexibility than non-amyloidogenic segments. Furthermore,
the presence of amyloidogenic segments in disordered proteins does not contradict the observation that
amyloidogenic segments are less ﬂexible.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Amyloid refers to a speciﬁc peptide or protein that is normally
soluble but is deposited as an insoluble aggregate under certain
physiological conditions [1]. More than two dozen human diseases,
including Alzheimer’s, Parkinson’s and Creutzfeldt-Jacob’s
neurodegenerative diseases, as well as type II diabetes and prion
diseases, are characterized by the formation of amyloid aggregates.
Additionally, several proteins and peptides not associated with
diseases also have the ability to form amyloid [2]. Remarkably,
amyloidogenic proteins having different primary sequences,
structures, functions, and lengths can form structurally similar
aggregates with similar physico-chemical properties [3,4].
The identiﬁcation of factors that inﬂuence the protein aggrega-
tion of amyloids is one of the fundamental problems that must be
addressed to understand the biogenesis of amyloid aggregates. One
way to approach this problem is to correlate features of theprimary sequence with its structure as determined by X-ray
crystallography or NMR. However, investigation of factors that
inﬂuence protein aggregation at the molecular level is not easy
because it is difﬁcult to crystallize amyloids and NMR limited to
small proteins. Furthermore, the comparison of features of non-
amyloidogenic segments with those of amyloidogenic segments
could reveal factors that encode messages underlying the forma-
tion of amyloids aggregates. This information can potentially aid
in the selection or development of therapeutic strategies to
prevent or cure amyloid diseases. The aim of this work is to analyze
and compare the primary amino acid sequences and structural
features of amyloidogenic sequences with non-amyloidogenic
sequences, especially with respect to their physico-chemical
features.
Besides hydrogen bonds, the observation that van der Waals
and hydrophobic interactions play a major role in aggregation for-
mation [5]. Simulation studies showed that hydrophobic interac-
tions are the principal driving force in these aggregations [6,7].
For amyloidogenic segments, speciﬁc side-chain and electrostatic
interactions play an important role in the assembly of the b con-
former [8]. The energetics of side chain conformation are now
known with some accuracy, and they depend on many factors,
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the electrostatic interactions that determine the structure and ﬂex-
ibility of biopolymers [10].
Conformational ﬂexibility is an inherent property of the protein
structure [11]. Solvent accessibility is correlated with ﬂexibility
[9,12]. Flexible residues are more often found on the surface than
in the core of proteins. Buried residues tend to be rigid, whereas
exposed residues tend to be ﬂexible [12]. The absolute value of sol-
vent accessibility for an amino acid is its accessible surface area
(ASA) in a protein structure. The relative solvent area (RSA) is
obtained by normalizing the ASA value over the maximum value
of the exposed surface area obtained for an extended tripeptide
conformation of Ala-X-Ala or Gly-X-Gly [13].
As another measure for peptide chain ﬂexibility, we chose the
temperature factors, i.e., B-values (also referred to as B-factors),
that are determined by X-ray crystallographic studies and provide
information about the local mobility of atoms. Analysis of B-factors
has provided novel insights into the ﬂexibility of amino acids [14].
The values of B-factors is deﬁned by 8p2 <u2> to the unidirectional
mean-square displacement, u2, averaged over the lattice [15].
In addition to B-factors, which are directly related to atomic
mobilities, the ﬂexibility of a protein can also be derived from
the trajectory of a molecular dynamics (MD) simulations by calcu-
lating the root mean-squared ﬂuctuations (RMSFs) of individual
atoms after removing the translational and rotational movements
[16]. Vibrations around equilibrium are not random but dependent
on local structure ﬂexibility. Some regions of the protein may be
ﬂexible, some regions may be stiffer. RMSFs capture the ﬂuctuation
of each atom around average positions. Usually the analysis of the
average atomic mobility of backbone atoms (N, Ca and C atoms)
during MD simulation gives insight into the ﬂexible and rigid
regions of proteins.
2. Materials and methods
2.1. Database preparation
Amyloidogenic segments and non-amyloidogenic segments
were found by surveying the literature. Only the segments vali-
dated by experimental evidence were included in this analysis.
Speciﬁcally, amyloidogenic segments that have been shown to
form amyloid ﬁbrils experimentally in vitro were used.
Three-dimensional structures of the proteins used in this work
were retrieved from the Protein Data Bank (PDB) [17]. The rules
for selecting atom co-ordinates were as follows: First, UniProt IDs
were used to search for a structure of the protein in PDB. Second,
for structures with identical regions, the structure with the longest
length of the protein was selected. Third, for structures with the
same length, the structure with the highest resolutionwas selected,
with a preference for single-protein structures over complexes.
Fourth, if the resolution was same, the structure with the smallest
R-value was selected. If all the structures retrieved were resolved
by NMR, the structures with the smallest RMSD were selected; in
the absence of RMSD, the structures submitted with the highest
numbers of conformers were selected. Thirty protein structures
met the above selection criteria andwere thus included in this anal-
ysis. These structures contain 81 amyloidogenic segments, as the
positive dataset and 99 non-amyloidogenic segments, as the nega-
tive dataset (in the Supplementary Tables 1 and 2).
2.2. Hydrogen bonds
Hydrogen bonds were calculated with the program hbplus [18]
using the generally recommended [18] and default [19] parame-
ters for angular and distance constraints between donor (D),
hydrogen (H), and acceptor (A) atoms and the atom covalentlybound to A (AA) [20]. The following default parameters were
applied for the calculation: maximum distances for D–A, 3.9 Å
and for H–A, 2.5 Å; minimum angles for D–H–A and D–A–AA,
90. These values are based on the extensive analysis reported pre-
viously [18,19].
Hydrogen bonds were counted for the entire segment. This
result was divided by the number of residues to yield the mean
value of hydrogen bonds for every segment.
2.3. Hydrophobicity
The hydrophobicity of each amino acid sequence was calculated
by the Kyte and Doolittle scale [21]. The residues included in the
hydrophobic category were Ala, Met, Cys, Phe, Leu, Val, Ile, Pro,
Tyr, Ser, Try, Thr, and Gly. The residues included in the hydrophilic
category were Arg, Lys, Asp, Gln, Glu and His. The mean hydropho-
bicity is deﬁned as the sum of the hydrophobicities of all residues
divided by the number of residues in the peptide segment.
2.4. Charge
The mean net charge is deﬁned as a net charge at pH 7.0 (total
number of negatively charged Asp + Glu and positively charged
Arg + Lys + His) divided by the total number of residues.
2.5. Electric potential
We used DS3.1 [22] to calculate the electrostatic potential of a
molecular system, which has DelPhi built in, a program that solves
the Poisson–Boltzmann equation on a cubical lattice using the
ﬁnite-difference technique. Atomic charges and radii for DelPhi
calculation were assigned using default charges and radii.
2.6. Surface accessibility
We used Naccess [23], which calculates the atomic and residue
accessible area. The program uses the Lee & Richards method [13],
whereby a probe of given radius is rolled around the surface of the
molecule, and the path traced out by its center is the accessible
surface. We also calculate the relative solvent area (RSA). This
calculation gave accessible surface area per residue for the amyloi-
dogenic and non-amyloidogenic segments. The mean RSA for each
segment is deﬁned as the sum of the RSA of all residues divided by
the number of residues in the peptide segment.
2.7. Chain ﬂexibility
The segments from NMR were excluded. We used the method
by Yuan [24] to normalize B-factors. Because thermal factors can
be affected by systematic errors such as the treatment of the sol-
vent and the weights and types of reﬁnement restraints, the ther-
mal factors were normalized to a zero mean and unit variance,
particularly for comparison amongst different structures. For each
segment, the B-value was normalized by the following equation:
B normalized ¼ ðB B meanÞ=B sigma
Where B-mean and B-sigma are, respectively, the mean value
and the standard deviation of the distribution of atomic thermal
factors for a given protein structure and B is the atomic thermal
factor as reported in the PDB ﬁle. Normalized B-factors derived
from the unbiased structures were used as a measure of the ﬂexi-
bility of the residues in the segment. We compared the absolute
value of mean normalized B-factors for amyloidogenic and non-
amyloidogenic segments. The mean normalized B-factors for each
segment is deﬁned as the mean of the normalized B-factors of all
residues divided by the number of residues in the peptide segment.
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We randomly selected 54 segments from the positive and
negative datasets for comparison. The ﬂexibility of the different
segments is revealed by looking at the root mean square ﬂuctua-
tion (RMSF) of each residue from its time-averaged position.
The Gromacs 4.5.5 software was used to perform molecular
dynamics simulations [25]. The C and N termini of peptides were
not capped according for the aggregation experiments. Under neu-
tral pH, Lys and Arg residues are positively charged, and Glu and
Asp are negatively charged. Charged systems were neutralized by
adding 0.05 M NaCl, according to the standard protocol. All simula-
tions were performed using the OPLS/AA force ﬁeld [26], in combi-
nation with a cubic box containing the SPC water model [27] and
using the periodic boundary condition. The distance of the box edge
from themolecule’s periphery was set to 0.7 nm. Initial energymin-
imization of the systemswith the steepest-descentmethod until the
maximumderivativewas lower than 1000.0 kJmol1nm1. After the
total energy of the system was nearly invariant upon further mini-
mization, equilibration was performed for 1500–23000 ps in a con-
stant-volume and constant-temperature conditions (NVT)
ensemble and was followed by a 100–300 ps constant-pressure
and constant-temperature conditions (NPT) ensemble. Finally, 11–
295 ns production runswere performed. The simulations of datasets
were run using the leapfrog Verlet algorithmwith a 1-fs integration
time step. Electrostatic interactions were calculated using Particle
Mesh Ewald (PME) summation with a grid size of 0.12 nm and a
real-space cutoff of 0.9 nm [28]. The temperature was set to
310 K, and the pressure was set to 1 bar. No constraints were intro-
duced for covalent bonds during simulation. A qualitative assess-
ment of the degree of equilibrium for each peptide was made as
follows. Cluster analysis was performed using g_cluster program
of the GROMACS software package with a cutoff of 0.2 nm and the
Gromos clustering algorithm proposed by Daura [29]. This method
observed convergence of a simulation by considering the number
of clusters as a function of time. The trajectorywas then divided into
two equal parts and the ﬁrst part compared with the second. Con-
vergence is deemed when samples from the same set of clusters
in the ﬁrst half of the trajectory as in the second half. For some seg-
ments, simulations were in the long run. If no more clusters appear
in one-third part of trajectory and the curve plateaus, convergence is
also deemed (in the Supplemental Figs. 1 and 2). The calculated root
mean square ﬂuctuation (RMSF) values were from the backbone (N,
Ca and C) atoms of peptides during simulations using the g_rmsf
command, which is a part of the GROMACS simulation package.
For the ﬁnal 5 ns of each simulation, RMSF values were calculated
and compared the ﬂexibility. The set up details of all MD simula-
tions are listed (in the Supplementary Tables 3 and 4).
Because the ﬁrst and last residues usually ﬂuctuate consider-
ably and can introduce bias, the C and N termini of peptides were
omitted from each structure. For each segment, the RMSF range
was generated by the following equation:
DRMSF ¼ RMSFmax RMSFmin
Where RMSFmax and RMSFmin are, respectively, the max value
and the min value of the RMSF for a given segment. DRMSF reﬂects
the range of ﬂuctuation. We compared the median DRMSF for
amyloidogenic and non-amyloidogenic segments. The mean
DRMSF for each segment is deﬁned as the mean of the DRMSF of
a segment divided by the number of residues in the peptide
segment.
2.9. Statistical analysis
The Mann–Whitney test and chi-square test were used for non-
normally distributed data and were calculated using SPSS software(Version 17.0 for Windows; SPSS Inc., Chicago, Illinois, USA). Signif-
icance was deﬁned at the p < 0.05 threshold.3. Results and discussion
In this study, the characterization and comparison of amyloido-
genic segments with non-amyloidogenic segments elucidated
factors that encode messages underlying the formation of
amyloids. A total of 81 amyloidogenic segments and 99 non-amy-
loidogenic segments were chosen for analysis, as validated by the
experimental evidence shown (in the Supplementary Tables 1
and 2). Speciﬁc physico-chemical properties of these amyloido-
genic and non-amyloidogenic segments, including H-bonds, hydro-
phobicity, charge, electrostatic potential, RSA, B-factor, and
DRMSF, are listed in Tables 1 and 2.3.1. Hydrogen bonds
Amyloidogenic segments have a higher median value of H-bond
(0.44) than non-amyloidogenic segments (0.30), with p value
0.0431 (Table 3). Amyloidogenic proteins display a high density
of hydrogen bonds that are solvent-exposed in the monomeric
structure. Because of the larger number of H-bonds, amyloidogenic
segments are more likely to be susceptible to attacks from water
molecules than non-amyloidogenic segments in similar situations.
During the formation of the cross-b, more hydrogen bonds will
provide more possibilities to form the hydrogen-bond stacks that
stabilize amyloid ﬁbril formation.3.2. Hydrophobicity
The median residue hydrophobicity for amyloidogenic
segments is much greater (0.18) than that for non-amyloidogenic
segments (6.00), with p value 2.6414e-05 (Table 3). This result
shows that amyloidogenic segments prefer a hydrophobic environ-
ment, indicating the importance of hydrophobic interactions for
amyloid structural determination.3.3. Charge
Amyloidogenic segments showed little difference median
values for positive charge, but lower median values for negative
charge and total charge (0.10; 0.11; 0.20) compared to non-amyloi-
dogenic segments (0.10; 0.14; 0.30), with p value 0.0991, 3.9412e-
04, and 0.0013, respectively (Table 3). Increase net charge can
interfere with the ability to form amyloid aggregates.
Therefore, we can conclude that a combination of a high overall
hydrophobicity and low net charge represents a unique structural
feature of amyloid segments.3.4. Electric potential
Comparison of the electrostatic potential of both segments
reveals a large difference between them. In general, amyloidogenic
segments displayed much lower median electrostatic potential
values (40.36) compared to non-amyloidogenic segments (60.32),
with a p value of 1.0368e-05 (Table 3). This result suggests that
lower electrostatic potentials facilitate the formation of cross-b
conformations. Amyloids show not only low net charge but also
lower electrostatic potential.
Increased H-bonds and reduced electrostatic potential most
likely represent another unique structural feature of amyloid
segments.
Table 1
Calculation hydrophobicity, hydrogen-bond, charge, electrostatic potential, B-factor, DRMSF frequency and accessible surface area in amyloidogenic segments.
Protein Region Length Hydrophobicity/
length
H-bond/
length
Charge/length Electrostatic
potential/
length
RSA/
length
B-factor/
length
DRMSF/
length
Positive Negative Total
Microtubule-associated protein tau 306–311 6 4.20 0.00 0.17 0.00 0.17 105.88 93.35
Amyloid beta A4 protein 672–711 40 2.40 0.68 0.15 0.15 0.30 16.69 19.78
683–697 15 1.80 0.67 0.20 0.13 0.33 52.87 11.13
684–694 11 5.39 0.64 0.27 0.18 0.45 77.61 10.60 0.0013
683–695 13 2.99 0.62 0.23 0.15 0.38 57.15 11.52 0.0009
682–696 15 0.90 0.60 0.20 0.20 0.40 52.85 10.46
681–697 17 3.06 0.59 0.18 0.18 0.35 46.31 11.50
680–698 19 6.84 0.63 0.16 0.16 0.32 40.81 12.26
679–699 21 11.55 0.62 0.19 0.14 0.33 36.81 13.42
678–700 23 15.41 0.61 0.17 0.17 0.35 34.30 13.57
677–701 25 17.00 0.68 0.20 0.16 0.36 29.09 13.34
Alpha-synuclein 61–78 18 16.74 0.78 0.00 0.06 0.06 11.58 62.35
63–78 16 23.84 0.69 0.00 0.00 0.00 10.48 61.26
61–73 13 5.46 0.54 0.00 0.08 0.08 20.88 62.96
66–74 9 16.74 0.44 0.00 0.00 0.00 32.24 58.51
71–82 13 10.53 0.85 0.00 0.15 0.15 39.62 67.91
Beta-2-microglobulin 79–91 13 0.65 0.08 0.10 0.20 0.30 12.62 4.24
73–82 10 4.60 0.10 0.10 0.10 0.20 78.45 7.96 0.0013
78–87 10 2.40 0.00 0.00 0.10 0.10 28.81 5.93 0.0019
83–92 10 0.00 0.10 0.10 0.40 0.50 21.39 3.04
88–97 10 18.80 0.60 0.11 0.16 0.26 84.52 8.02
103–108 6 0.18 0.67 0.16 0.16 0.32 81.42 18.15
84–89 6 0.78 0.17 0.19 0.13 0.31 66.97 1.53 0.0009
111–116 6 3.30 0.17 0.13 0.13 0.25 143.57 6.97
78–83 6 7.38 0.00 0.32 0.16 0.47 135.10 9.05 0.0012
82–87 6 6.48 0.00 0.00 0.13 0.13 30.45 0.85
40–61 22 2.20 0.05 0.15 0.15 0.30 14.85 8.41
103–109 7 3.71 0.57 0.08 0.08 0.17 46.30 19.10
Myoglobin 2–20 19 8.17 0.84 0.00 0.22 0.22 24.92 37.67 0.0016
5–35 31 3.41 0.84 0.00 0.13 0.13 21.61 25.87 0.000
21–36 16 1.76 0.88 0.10 0.10 0.20 51.82 18.06 0.001
Myoglobin 1–29 29 6.38 0.86 0.12 0.06 0.18 30.93 32.34
101–118 18 10.26 0.94 0.16 0.20 0.36 40.30 23.92 0.001
Myohemerithrin 40–63 24 5.04 1.08 0.06 0.25 0.31 14.42 31.99 0.001
69–87 19 9.69 0.84 0.20 0.10 0.30 39.05 37.74 0.000
Plastocyanin 1–15 15 20.85 0.40 0.40 0.10 0.50 32.31 1.49
24–43 20 7.20 0.10 0.10 0.00 0.10 27.72 4.84
46–57 12 12.72 0.50 0.17 0.00 0.17 42.98 14.55
57–74 18 0.36 0.22 0.00 0.17 0.17 25.78 21.06 0.0019
67–74 8 5.60 0.00 0.33 0.17 0.50 31.66 24.55
Glutathione S-transferase P 145–164 20 6.00 0.85 0.17 0.17 0.33 17.96 11.34 0.001
Chemotaxis protein CheY 90–106 17 1.36 0.59 0.00 0.00 0.00 51.32 37.66 0.001
PL B1 protein 132–156 25 30.50 0.60 0.00 0.17 0.17 35.99 10.34
Immunoglobulin G-binding protein G 412–427 16 15.04 0.63 0.00 0.17 0.17 41.78 8.28
Human prion protein 176–185 10 5.10 0.80 0.00 0.17 0.17 86.02 36.70 0.001 0.0026
178–191 14 0.56 0.93 0.00 0.00 0.00 25.53 39.39 0.002 0.0013
Lysozyme C 23–32 10 9.70 0.70 0.17 0.00 0.17 82.46 29.94 0.003 0.0016
43–52 10 6.80 0.60 0.09 0.14 0.23 41.37 11.25 0.005 0.0014
Islet amyloid polypeptide 55–60 6 9.00 0.33 0.14 0.00 0.14 57.48 8.48 0.001
48–53 6 6.00 0.17 0.00 0.00 0.00 59.05 8.13 0.0006
55–62 8 7.44 0.38 0.00 0.00 0.00 53.75 13.34 0.0013
63–70 8 6.72 0.38 0.22 0.00 0.22 96.56 28.71
43–51 9 1.71 0.33 0.00 0.00 0.00 55.66 8.23 0.0026
53–60 8 4.72 0.38 0.11 0.00 0.11 35.31 10.73 0.0014
47–55 9 4.50 0.33 0.08 0.00 0.08 45.09 9.56 0.0028
Transthyretin 30–40 11 17.38 0.18 0.09 0.09 0.18 34.73 23.64
125–135 11 9.24 0.18 0.00 0.00 0.00 10.21 20.17 0.001
Gelsolin 209–219 11 1.21 0.18 0.00 0.18 0.18 34.25 7.95 0.002 0.0009
Lactotransferrin 556–563 8 7.44 0.00 0.00 0.13 0.13 43.18 15.14 0.004
Eukaryotic peptide chain release
factor GTP-binding subunit
7–13 7 19.18 0.29 0.14 0.07 0.21 60.03 99.97
Insulin 36–41 6 8.82 0.33 0.00 0.00 0.00 89.55 19.33 0.008 0.0009
102–107 6 4.20 0.33 0.10 0.10 0.20 76.93 48.48 0.005
35–40 6 8.82 0.33 0.10 0.10 0.20 79.93 8.15 0.007 0.0006
Ribonuclease pancreatic 20–25 6 5.40 0.33 0.29 0.00 0.29 81.95 50.65 0.010
22–32 11 6.71 0.18 0.00 0.09 0.09 13.71 55.30 0.002
75–80 6 2.52 0.33 0.14 0.18 0.32 58.10 33.07 0.007
Beta-lactoglobulin 11–20 10 3.50 0.40 0.11 0.17 0.29 51.56 34.90 0.001 0.0027
101–110 10 1.80 0.00 0.09 0.19 0.28 40.36 13.34 0.004 0.0016
146–152 7 0.91 0.00 0.00 0.00 0.00 57.96 53.77
Apolipoprotein C-II 60–70 11 2.42 0.55 0.00 0.06 0.06 50.50 8.67
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Cold shock protein CspB 1–22 22 5.28 0.36 0.08 0.17 0.25 41.64 39.03
1–35 35 3.50 0.54 0.07 0.17 0.24 28.20 39.02
36–67 32 18.88 0.47 0.22 0.11 0.33 26.19 45.95
Transforming growth factor-beta-
induced protein ig-h3
515–525 11 17.49 0.82 0.20 0.13 0.33 16.85 6.63 0.0024
515–532 18 16.38 0.78 0.20 0.07 0.27 17.89 5.34 0.001
Laminin subunit alpha-1 2919–2930 12 12.72 0.25 0.00 0.00 0.00 39.83 21.62 0.002
Prolactin 7–21 15 4.35 0.20 0.14 0.16 0.30 48.36 11.67 0.0015
20–34 15 0.75 0.80 0.27 0.00 0.27 31.39 6.25 0.001
71–85 15 10.35 0.20 0.00 0.00 0.00 33.67 13.37
Replication protein 26–34 9 25.38 0.67 0.00 0.00 0.00 40.58 18.19 0.002
Transcription elongation 430–466 37 49.21 0.38 0.00 0.00 0.00 30.83 13.15
Regulator 1
Median 0.18 0.44 0.10 0.11 0.20 40.36 13.57 0.002 0.0013
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The residues from the amyloidogenic segments showed a signif-
icantly lower median value of relative accessible surface area
(13.57% RSA) compared to residues from the non-amyloidogenic
segments (29.19% RSA), with a p value of 0.0374 (Table 3). There-
fore, this result shows that amyloidogenic segments have a much
lower average surface accessibility than non-amyloidogenic
segments. It is likely that amyloidogenic segments minimize their
solvent-accessible surface area. This tendency is consistent with
the result demonstrating that median residue hydrophobicity for
amyloidogenic segments is much greater than that for non-amyloi-
dogenic segments. Amyloidogenic segments are thus more likely to
occur in proteins with a hydrophobic core buried inside. This is
most likely one of the most important characteristics of amyloido-
genic segments. To prevent water-mediated attacks on the H-bond,
residues of the amyloidogenic segments must be shielded from the
solvent, and this necessity is reﬂected in a low RSA for
amyloidogenic segments.
3.6. Chain ﬂexibility
Very interestingly, amyloidogenic segments have a signiﬁcantly
lower median value for normalized B-factors (0.002) than non-
amyloidogenic segments (0.024), with a p value of 2.9924e-10
(Table 3). This result suggests that the residues in amyloidogenic
segments are less ﬂexible than those in the non-amyloidogenic
segments because ﬂexible residues are more often found on the
surface than in the core of proteins, while buried residues incline
to be rigid. This result is consistent with the ﬁnding that amyloido-
genic segments minimize solvent-accessible surface area and are
buried in a protein’s interior.
3.7. Molecular dynamics simulation
Quite unexpectedly, our dynamic simulation studies support
that a model in which amyloidogenic segments have lower average
ﬂexibility relative to non-amyloidogenic segments, which seems to
suggest that these regions are associated with the rigid core of the
protein. This result tallies with the ﬁnding of a previous study by
Tartaglia et al. [30] which reports that the regions of the amino
acid sequence that are highly aggregation-prone should be
protected in the folded state and buried in the native state before
they can form stable intermolecular interactions.
MD simulation of datasets shows that amyloidogenic segments
have a slightly lower median values for DRMSF (0.0013) compared
to non-amyloidogenic segments (0.002), with a p value of 0.0029
(Table 3). This tendency supports the observation based on nor-
malized B-factors that amyloidogenic segments are less ﬂexible.
Taken together, it is worth noting that the B-factor suggests that
amyloidogenic segments are less ﬂexible, and the range of RMSF
ﬂuctuations during MD simulations also supports this observation.This result differs from tau aggregation in Alzheimer’s disease,
where tau protein has been shown to exist as a disorder protein.
Through a deep analysis of our data, we arrive at the exciting ﬁnd-
ing that amyloidogenic segments are located in rigid regions of the
protein and rarely in the disordered regions. In fact, loop coverage
is a common strategy employed to avoid aggregation [31].
Additionally, using packing density as a parameter to predict
amyloidogenic and disordered regions in protein chains, Galzits-
kaya and co-workers found that a stronger than expected packing
density is responsible for amyloid formation. They further demon-
strated that the regions with a weaker than expected packing den-
sity are responsible for the appearance of disordered regions [32].
To validate this exciting ﬁnding of our disorder prediction and its
relationship with aggregation, we also calculated the packing
density. Disorder prediction and packing density of amyloidogenic
segments and non-amyloidogenic segments are listed (in the Sup-
plementary Tables 5 and 6). The chi-square test results show that
the overall difference between amyloidogenic and non-amyloido-
genic segments in predicting segment disorder is signiﬁcant; amy-
loidogenic segments are less disordered than non-amyloidogenic
segments, with a p value of 0.0071 (in the Supplementary Table 7).
In addition, amyloidogenic segments have a signiﬁcantly higher
median value for packing density (21.4) than non-amyloidogenic
segments (20.86), with a p value 3.3470e-04, whereas disordered
segments have a signiﬁcantly lower packing density (21.1) than
ordered segments (20.4), with a p value 7.2851e-04 (in the Supple-
mentary Table 8). These results are consistent with the ﬁndings of
Galzitskaya and co-workers’ [32]. Therefore, from both prediction
and digital analysis, we veriﬁed that amyloidogenic segments are
preferentially located in rigid regions of the protein and rarely in
the disordered regions. This ﬁnding represents a potential differ-
ence between amyloidgenic and disordered regions. We also
investigated the parent proteins of these amyloidogenic and non-
amyloidogenic segments in DisProt (Database of Protein Disorder),
and we found that 8 in 30 of these proteins are disordered. Unsur-
prisingly, the amyloidogenic segments in these disordered proteins
are located in rigid regions of the protein and only rarely in the dis-
ordered regions (in the Supplementary Tables 9 and 10). This result
further validates our other ﬁndings. The presence of amyloidogenic
segments in disordered proteins does not contradict the fact that
amyloidogenic segments are less ﬂexible. This is a very exciting
ﬁnding and conﬁrm that amyloidgenic segments are less ﬂexible
than non-amyloidgenic segments.
In summary, amyloidogenic segments are characterized by a
lower average ﬂexibility, lower average net charge, lower average
electrostatic potential, and lower average RSA and B-factor than
non-amyloidogenic segments. However, amyloidogenic segments
are enriched in hydrophobic residues and show the presence of
more hydrogen bonds.
Here, we have investigated and characterized some of the
features of amyloidogenic sequences. The phenomenon of protein
aggregation is a ubiquitous problem in biomedical and
Table 2
Calculation hydrophobicity, hydrogen-bond, charge, electrostatic potential, B-factor, DRMSF frequency and accessible surface area in non-amyloidogenic segments.
Protein Region Length Hydrophobiciy/
length
H-bonds/
length
Charge/length Electrostatic
potential/lengh
RSA/
length
B-factor/
length
DRMSF/
length
Positive Negative Total
Amyloid beta A4 protein 687–691 5 9.70 0.20 0.00 0.20 0.20 223.88 12.84
686–692 7 7.98 0.43 0.00 0.14 0.14 104.83 10.46 0.0019
685–693 9 1.26 0.67 0.11 0.22 0.33 63.62 9.27
Beta-2-microglobulin 21–36 16 17.60 0.06 0.06 0.25 0.31 13.57 5.64 0.0019
37–49 13 4.81 0.08 0.00 0.08 0.08 10.64 3.82
50–61 12 0.96 0.08 0.25 0.17 0.42 34.13 12.71 0.0022
62–79 18 23.94 0.17 0.28 0.22 0.50 40.19 15.98
107–119 13 11.44 0.08 0.15 0.23 0.38 68.61 18.99
23–32 10 12.10 0.10 0.00 0.30 0.30 48.31 6.03 0.0012
28–37 10 15.90 0.00 0.10 0.20 0.30 30.66 5.80
33–42 10 15.80 0.20 0.10 0.20 0.30 78.14 3.93
43–52 10 2.50 0.00 0.00 0.10 0.10 13.64 5.19 0.0021
48–57 10 2.30 0.10 0.20 0.10 0.30 40.96 15.48
53–62 10 2.40 0.10 0.30 0.10 0.40 43.23 14.31
58–67 10 10.70 0.30 0.30 0.20 0.50 112.86 19.29
63–72 10 14.60 0.10 0.30 0.30 0.60 93.82 20.42
68–77 10 5.70 0.10 0.20 0.20 0.40 39.79 9.02
93–102 10 12.40 0.40 0.30 0.20 0.50 61.81 5.94 0.0092
98–107 10 3.30 0.40 0.00 0.20 0.20 40.82 4.75
103–112 10 4.70 0.40 0.00 0.20 0.20 63.25 18.17
Regulatory protein cro 51–70 20 6.40 0.50 0.05 0.15 0.20 44.86 13.55
Myoglobin 35–40 6 13.68 0.50 0.17 0.33 0.50 167.55 36.87 0.087
37–51 15 22.20 0.60 0.20 0.40 0.60 98.21 39.94 0.021
52–58 7 6.09 0.71 0.29 0.14 0.43 183.13 45.80 0.027 0.0028
59–78 20 6.80 1.00 0.10 0.20 0.30 48.66 29.97 0.001
79–86 8 19.84 0.38 0.25 0.50 0.75 196.98 46.08 0.029
86–95 10 5.30 0.90 0.10 0.20 0.30 55.64 27.76 0.022
95–101 7 7.00 0.14 0.00 0.43 0.43 141.33 37.61 0.020
Myohemerithrin 1–18 18 8.46 0.33 0.22 0.06 0.28 31.53 44.82 0.0025
109–118 10 11.40 0.40 0.10 0.30 0.40 143.76 34.47
18–38 21 20.16 1.10 0.29 0.24 0.52 39.47 28.12 0.008
37–41 5 10.50 0.20 0.20 0.20 0.40 136.74 48.64 0.050
63–70 8 5.20 0.25 0.25 0.13 0.38 111.30 49.30 0.006
86–92 7 3.50 0.00 0.14 0.00 0.14 113.43 47.99 0.044 0.0018
93–108 16 9.92 0.75 0.13 0.25 0.38 53.14 24.63 0.014
Plastocyanin 1–8 8 10.48 0.00 0.13 0.00 0.13 41.46 2.38 0.0013
7–12 6 2.10 0.33 0.17 0.00 0.17 93.32 1.47
11–20 10 10.30 0.10 0.10 0.00 0.10 41.22 2.18
17–21 5 1.90 0.00 0.20 0.00 0.20 117.34 3.82
17–26 10 8.30 0.20 0.20 0.10 0.30 66.47 7.54
26–33 8 1.52 0.00 0.00 0.25 0.25 81.03 5.36
26–37 12 3.96 0.08 0.00 0.25 0.25 43.40 4.01 0.0028
30–39 10 10.80 0.10 0.00 0.20 0.20 55.49 1.34 0.0014
36–47 12 8.16 0.25 0.33 0.08 0.42 34.78 4.19 0.0013
45–50 6 4.98 0.17 0.17 0.00 0.17 68.18 8.78 0.001
51–56 6 2.28 0.83 0.17 0.17 0.33 197.03 18.18 0.0045
57–63 7 2.59 0.14 0.43 0.00 0.43 109.00 19.10
61–70 10 5.10 0.30 0.20 0.00 0.20 46.94 19.18 0.0028
64–70 7 9.17 0.29 0.14 0.00 0.14 59.17 20.96 0.0036
65–69 5 4.40 0.20 0.20 0.00 0.20 129.98 25.14
68–73 6 2.22 0.00 0.17 0.00 0.17 47.58 29.60 0.0014
72–80 9 3.24 0.22 0.11 0.11 0.22 74.68 13.01 0.0021
79–84 6 1.20 0.00 0.00 0.00 0.00 30.08 1.07
92–99 8 6.00 0.13 0.00 0.13 0.13 45.00 1.98
Pancreatic trypsin inhibitor 51–63 13 2.21 0.31 0.00 0.23 0.23 40.23 39.12 0.018
Glutathione S-transferase P 80–107 28 6.44 1.04 0.21 0.11 0.32 27.86 20.99 0.010
109–133 25 23.50 0.92 0.20 0.20 0.40 44.86 35.09 0.013
172–183 12 12.00 0.83 0.00 0.08 0.08 30.78 28.14 0.012 0.0015
185–192 8 5.28 0.63 0.00 0.25 0.25 117.43 39.31 0.019
Human prion protein 121–130 10 15.00 0.10 0.00 0.00 0.00 21.24 50.26 0.0027
126–135 10 5.30 0.00 0.00 0.00 0.00 25.55 54.98 0.035
131–140 10 1.40 0.00 0.00 0.20 0.20 34.78 58.62 0.054
141–150 10 17.30 0.60 0.30 0.10 0.40 81.35 53.16 0.013
146–155 10 26.90 0.80 0.30 0.30 0.60 98.20 35.77 0.005
151–160 10 27.20 0.30 0.10 0.30 0.40 48.79 34.25 0.025 0.0015
156–165 10 18.90 0.00 0.00 0.20 0.20 27.92 30.66 0.012
161–170 10 11.70 0.30 0.20 0.10 0.30 60.32 48.14 0.012
166–175 10 18.40 0.20 0.20 0.00 0.20 50.70 62.15 0.007
171–180 10 7.00 0.60 0.10 0.10 0.20 48.54 46.26 0.062
181–190 10 3.00 0.90 0.00 0.20 0.20 69.00 39.34 0.039 0.0015
186–195 10 10.30 0.30 0.00 0.20 0.20 46.68 54.43 0.029
191–200 10 14.80 0.30 0.20 0.10 0.30 67.32 58.28 0.045
196–205 10 10.40 0.60 0.30 0.10 0.40 70.25 46.52 0.025
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201–210 10 0.30 0.70 0.20 0.20 0.40 99.00 47.48 0.015
206–215 10 4.20 0.70 0.20 0.10 0.30 65.51 54.94 0.009
211–220 10 11.60 0.80 0.20 0.10 0.30 70.39 56.40 0.024
216–225 10 20.80 0.90 0.20 0.10 0.30 71.79 62.43
Lysozyme C 28–37 10 8.40 0.40 0.10 0.30 0.40 90.09 40.13 0.047
33–42 10 1.10 0.40 0.10 0.10 0.20 57.47 40.87 0.030
38–47 10 0.80 0.60 0.00 0.10 0.10 47.30 25.80 0.037
48–57 10 6.00 0.60 0.10 0.10 0.20 62.52 20.20 0.021
53–62 10 17.10 0.30 0.10 0.10 0.20 42.54 33.13 0.051
58–67 10 14.50 0.00 0.10 0.10 0.20 29.66 51.51 0.005
63–72 10 17.70 0.60 0.20 0.10 0.30 69.93 40.54 0.023
68–77 10 2.90 0.40 0.10 0.10 0.20 38.03 10.81 0.030
73–82 10 2.90 0.40 0.00 0.10 0.10 27.63 11.95 0.038
78–87 10 19.60 0.40 0.10 0.20 0.30 81.16 32.96 0.050
83–92 10 5.50 0.30 0.10 0.10 0.20 94.94 46.43 0.008 0.0025
88–97 10 4.70 0.20 0.00 0.10 0.10 22.48 40.54 0.002
93–102 10 7.90 0.70 0.00 0.10 0.10 32.24 29.78 0.030
103–112 10 3.90 0.30 0.20 0.00 0.20 65.28 35.95 0.042
108–117 10 6.20 0.70 0.10 0.20 0.30 110.70 19.34 0.028
113–122 10 8.80 0.60 0.10 0.30 0.40 86.28 29.19 0.042
118–127 10 8.20 0.40 0.10 0.20 0.30 77.02 33.98 0.028
123–132 10 2.00 0.70 0.00 0.20 0.20 59.15 29.19 0.023
128–137 10 16.20 0.70 0.00 0.30 0.30 72.43 43.59 0.001 0.002
133–142 10 22.10 0.30 0.10 0.30 0.40 76.66 46.04 0.003 0.0013
138–147 10 6.20 0.40 0.10 0.10 0.20 45.46 50.17 0.002
Ribonuclease pancreatic 33–38 5 10.25 0.00 0.17 0.33 0.5 121.75 43.78 0.057
Median 6.00 0.30 0.10 0.14 0.30 60.32 29.19 0.026 0.002
Table 3
Comparation hydrogen-bond, hydrophobicity, charge, electrostatic potential, B-factor, DRMSF frequency and accessible surface area in amyloidogenic segments with non-
amyloidogenic segments.
Amyloidogenic segments Median (QR)a Non-amyloidogenic segments Median (QR) Mann–Whitney test p-valueb
H-bond/length 0.4 (0.5) 0.3 (0.5) 0.0431 ⁄
Hydrophobicity/length 0.18 (11.87) 6.00 (13.10) 2.6414e05 ⁄⁄⁄
Positive charge/length 0.10 (0.17) 0.10 (0.20) 0.0991
Negative charge/length 0.11 (0.17) 0.14 (0.10) 3.9412e04 ⁄⁄⁄
Total charge/length 0.20 (0.21) 0.30 (0.20) 0.001 ⁄⁄
Electrostatic potential/length 40.36 (28.58) 60.32 (48.11) 1.0368e05 ⁄⁄⁄
RSA/length 13.57 (24.91) 29.19 (31.59) 0.0374 ⁄
B-factor/length 0.002 (0.0033) 0.024 (0.0257) 2.9924e10 ⁄⁄⁄
DRMSF/length 0.0013 (0.0008) 0.002 (0.0012) 0.0029 ⁄⁄
a QR, Quartile range.
b Asterisks representative signiﬁcance (p), ⁄<0.05; ⁄⁄<0.01; ⁄⁄⁄<0.001.
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fundamental differences in the characteristics of amyloidogenic
and non-amyloidogenic segments, which could be useful when
designing a therapeutic regimen for the treatment of diseases
involving protein aggregation.
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